Shots:

• The two companies collaborated for the development of Foundation Medicine’s tissue & blood-based CDx to be used with marketed and investigational treatments in Takeda’s late-stage lung cancer portfolio
• If approved- the CDx will be used to identify patients who may be eligible for mobocertinib for EGFR Exon20 insertion + mNSCLC and Alunbrig (brigatinib) for patients with TKI-naïve mNSCLC
• Under the agreement- Foundation Medicine will leverage its FoundationOne CDx and FoundationOne Liquid CDx for Takeda’s therapies. The US FDA’s approved CDx allow oncologists to identify patients who may be appropriate for FDA-approved targeted therapies

­ Ref: PRNewswire | Image:Takeda